Literature DB >> 3030954

Distribution and properties of beta-adrenergic receptors in human iris-ciliary body.

M B Wax, P B Molinoff.   

Abstract

beta-Adrenergic receptors from the iris-ciliary body of human eyes removed shortly after death were studied using membranes prepared by isopycnic centrifugation of tissue homogenates. This procedure separates uveal melanin pigment from plasma membranes and reduces nonspecific binding of 125I-iodopindolol. The observed binding of 125I-iodopindolol was of high affinity (Kd = 78 +/- 6.6 pM), saturable, and fully reversible (t1/2 = 4.6 min). Scatchard plots were linear and revealed a Bmax of 134 +/- 20 fmol/mg of protein from the whole iris-ciliary body. The affinities of the receptors for a series of agonists and antagonists were determined. The order of potency for the inhibition of the binding of the radioligand by antagonists was ICI 118,551 greater than MK950 greater than propranolol greater than ICI 89,406 greater than metoprolol. This order of potency is characteristic of beta-adrenergic receptors of the beta 2 subtype. Preparations of iris-ciliary body were also subjected to microdissection prior to density gradient centrifugation to permit the study of beta-adrenergic receptors in the ciliary processes, ciliary body, and iris. Each of these regions was found to contain approximately one third of the total number of beta-adrenergic receptors in the human iris-ciliary body. The highest density of receptors was located in the ciliary processes (180 +/- 40 fmol/mg of protein), while the density of receptors in the iris (98 +/- 7.5 fmol/mg of protein) and ciliary body (less the processes) (42 +/- 17 fmol/mg of protein) was notably lower. Only beta 2-adrenergic receptors are detectable by competition experiments in the iris-ciliary body as a whole, or in the individual preparations of iris, ciliary processes, or ciliary body; however, microdissection and analysis of beta-adrenergic receptor subtypes in isolated ciliary muscle permitted detection of a small number of beta 1-adrenergic receptors. beta 1-Adrenergic receptors comprised about 10% of the total number of beta-adrenergic receptors in the whole iris-ciliary body. The finding that most of the beta-adrenergic receptors in the human iris-ciliary body are of the beta 2 subtype may be of significant therapeutic importance in the medical management of glaucoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030954

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  24 in total

1.  In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma.

Authors:  Tamara Martínez; Maria Victoria González; Ingo Roehl; Natalia Wright; Covadonga Pañeda; Ana Isabel Jiménez
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

Review 2.  Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.

Authors:  R L Juliano; K Carver; C Cao; X Ming
Journal:  J Drug Target       Date:  2012-11-19       Impact factor: 5.121

Review 3.  Topical drug therapy in glaucoma.

Authors:  Hemma Resch; Gerhard Garhofer
Journal:  Wien Med Wochenschr       Date:  2006-09

Review 4.  Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  M M Buckley; K L Goa; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

5.  Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension.

Authors:  Luciano Quaranta; Raffaele Turano; Teodoro Pizzolante
Journal:  Clin Ophthalmol       Date:  2007-06

6.  Opposing effects of atropine and timolol on the color and luminance emmetropization mechanisms in chicks.

Authors:  Laura A Goldberg; Frances J Rucker
Journal:  Vision Res       Date:  2016-03-19       Impact factor: 1.886

7.  Autonomic drugs and the accommodative system in rhesus monkeys.

Authors:  Lisa A Ostrin; Adrian Glasser
Journal:  Exp Eye Res       Date:  2009-09-24       Impact factor: 3.467

8.  Pharmacogenetics of ophthalmic topical beta-blockers.

Authors:  Duska J Sidjanin; Catherine A McCarty; Richard Patchett; Edward Smith; Russell A Wilke
Journal:  Per Med       Date:  2008       Impact factor: 2.512

9.  Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma.

Authors:  Kivanc Güngör; Mehtap Ozkur; Ingolf Cascorbi; Jürgen Brockmöller; Necdet Bekir; Ivar Roots; A Sükrü Aynacioglu
Journal:  Eur J Clin Pharmacol       Date:  2003-09-12       Impact factor: 2.953

10.  Progress toward personalized medicine for glaucoma.

Authors:  Sayoko E Moroi; Duna A Raoof; David M Reed; Sebastian Zöllner; Zhaohui Qin; Julia E Richards
Journal:  Expert Rev Ophthalmol       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.